ZYBAN

I appreciate your detailed instructions, but

I need to clarify an important issue with the source documents provided.

The documents describe **CONTRAVE** (naltrexone hydrochloride and bupropion hydrochloride fixed-combination tablets for weight management), not **ZYBAN** (bupropion hydrochloride for smoking cessation or depression).

The sources are: 1. **Document 1**: Comprehensive Australian Product Information for CONTRAVE 8/90 2. **Document 2**: ARTG registration for ZYBAN SR 150 mg (bupropion monotherapy) 3. **Document 3**: PBS listing for ZYBAN 150 mg tablet

These are two different medicines: — **ZYBAN**: bupropion monotherapy, indicated for smoking cessation or depression — **CONTRAVE**: naltrexone + bupropion combination, indicated for weight management

Document 1 contains extensive clinical and safety information, but it is for CONTRAVE, not ZYBAN. Documents 2 and 3 confirm ZYBAN exists but provide minimal detail.

**I cannot ethically write a Brand Dossier for ZYBAN using CONTRAVE's product information**, as this would: — Misrepresent the indications (weight management vs. smoking cessation/depression) — Misrepresent the formulation (fixed combination vs. monotherapy) — Provide incorrect dosing and safety guidance

**Could you please clarify:** 1. Should I write the dossier for **CONTRAVE** (using Document 1 as the primary source)? 2. Or do you have additional source documents for **ZYBAN** that describe its therapeutic indications, dosing, safety profile, and clinical use?

I'm ready to proceed once this is resolved.